Biagio Ricciuti, Thoracic Medical Oncologist at the Dana-Farber Cancer Institute, shared a post on X about a recent paper by Jacob Sands, Medical Oncologist at Dana-Farber Cancer Institute, published in Journal of Clinical Oncology:

“Datopotamab Deruxtecan in Advanced or Metastatic NSCLC With Actionable Genomic Alterations: Phase II TROPION-Lung05 Study.

ORR in all patients: 35.8%
In EGFR+ NSCLC: ORR 43.6%, PFS 5.8 mo, OS 18.3 mo
Grade ≥3 TRAEs: 28.5% of patients with 5 patients experienced treatment-related ILD.”

“Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study”

Authors: Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Rachel Chiaverelli, Luis Paz-Ares et al.

Biagio Ricciuti: Datopotamab Deruxtecan in Advanced/Metastatic NSCLC by Jacob Sands et al.

More posts featuring Biagio Ricciuti.

Biagio Ricciuti is a Thoracic Medical Oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.